SC
EPRX

SummitTX Capital’s Eupraxia Pharmaceuticals EPRX Stock Holding History

SummitTX Capital’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.37M Buy
327,997
+152,049
+86% +$1.22M 0.07% 275
2025
Q4 		$1.33M Buy
+175,948
New +$1.08M 0.04% 367

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

SummitTX Capital's EPRX Position: Q1 2026 in Review

SummitTX Capital increased its Eupraxia Pharmaceuticals (EPRX) stake by 86% in Q1 2026, buying an estimated $1.22M and bringing the position to 327,997 shares worth $2.37M. The position accounts for 0.07% of the portfolio, ranked #275.

SummitTX Capital first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • SummitTX Capital held 327,997 shares of Eupraxia Pharmaceuticals worth $2.37M as of Q1 2026.
  • SummitTX Capital bought 152,049 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $1.22M.
  • Eupraxia Pharmaceuticals made up 0.07% of SummitTX Capital's portfolio in Q1 2026, its #275 holding.
  • SummitTX Capital first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on SummitTX Capital's 13F filing for Q1 2026, filed 15 May 2026.